{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=37",
    "query": {
      "condition": "Leukemia, Myelogenous, Acute",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 2504,
    "total_pages": 251,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T15:38:00.728Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02807272",
      "title": "Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myelomonocytic, Chronic"
      ],
      "interventions": [
        {
          "name": "Tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kura Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2017-01-10",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-17",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807272"
    },
    {
      "nct_id": "NCT07661095",
      "title": "A Study of CRD3874-SI in People With Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "AML",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "CRD3874-SI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-06-15",
      "completion_date": "2028-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07661095"
    },
    {
      "nct_id": "NCT07347418",
      "title": "CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Acute Myeloid Leukemia (AML)",
        "Relapsed Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndrome",
        "AML (Acute Myeloid Leukemia)"
      ],
      "interventions": [
        {
          "name": "CD64 CAR T Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2026-12",
      "completion_date": "2032-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07347418"
    },
    {
      "nct_id": "NCT00651261",
      "title": "Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "midostaurin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "dexamethasone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 717,
      "start_date": "2008-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2021-08-18",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 170,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651261"
    },
    {
      "nct_id": "NCT03848754",
      "title": "Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Adult AML"
      ],
      "interventions": [
        {
          "name": "Gemtuzumab Ozogamicin 3 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab Ozogamicin 2 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Pracinostat - 45 mg",
          "type": "DRUG"
        },
        {
          "name": "Pracinostat - 60 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-05-24",
      "completion_date": "2021-05-05",
      "has_results": false,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03848754"
    },
    {
      "nct_id": "NCT07819396",
      "title": "Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Leukemia",
        "Acute Leukemia of Ambiguous Lineage",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Undifferentiated Leukemia",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Burkitt Leukemia",
        "Burkitt Lymphoma",
        "Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Lymphoblastic Lymphoma",
        "Mast Cell Leukemia",
        "Mixed Phenotype Acute Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic CD34+-enriched and CD45RA-depleted PBSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 52,
      "start_date": "2027-01-01",
      "completion_date": "2031-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07819396"
    },
    {
      "nct_id": "NCT00637052",
      "title": "A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced MDS",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "ARRY-520, KSP(Eg5) inhibitor; intravenous",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2008-03-18",
      "completion_date": "2010-06-21",
      "has_results": false,
      "last_update_posted_date": "2021-02-08",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00637052"
    },
    {
      "nct_id": "NCT00450983",
      "title": "Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "muromonab-CD3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "natural killer cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 1,
      "start_date": "2006-12",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-24",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00450983"
    },
    {
      "nct_id": "NCT03723057",
      "title": "Expanded Access for AG-221",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "AG-221",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-10-24",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 1,
      "location_summary": "Summit, New Jersey",
      "locations": [
        {
          "city": "Summit",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03723057"
    },
    {
      "nct_id": "NCT00003243",
      "title": "Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "1998-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-03-10",
      "last_synced_at": "2026-10-17T15:38:00.728Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003243"
    }
  ]
}